Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

Rupert Bartsch; Simon Peter Gampenrieder; Gabriel Rinnerthaler; Edgar Petru; Daniel Egle; Andreas Petzer; Marija Balic; Ursula Pluschnig; Thamer Sliwa; Christian Singer

doi:10.1007/s00508-021-01987-9

Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

Wien Klin Wochenschr. 2022 Jan;134(1-2):63-72. doi: 10.1007/s00508-021-01987-9. Epub 2022 Jan 28.

Authors

Affiliations

¹ Department of Medicine I, Division of Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
² Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48, 5020, Salzburg, Austria.
³ University Hospital for Gynecology and Obstetrics, Clinical Department of Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.
⁴ Department of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
⁵ Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz GmbH, Seilerstätte 4, 4010, Linz, Austria.
⁶ Department of Internal Medicine, Division of Clinical Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
⁷ Department of Internal Medicine and Hematology and Internal Oncology, Klagenfurt Hospital, Feschnigstraße 11, 9020, Klagenfurt am Wörthersee, Austria.
⁸ 3rd Medical Department, Hematology and Oncology, Hanusch Hospital, Heinrich-Collin-Straße 30, 1140, Vienna, Austria.
⁹ Department of Gynecology, Breast Cancer Center Vienna, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. [email protected].

Abstract

A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

Keywords: Antibody-conjugate; HER2; Pertuzumab; Trastuzumab; Tyrosin-kinase inhibitor.

MeSH terms

Algorithms
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Austria
Breast Neoplasms* / drug therapy
Female
Humans
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / therapeutic use
Trastuzumab / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Receptor, ErbB-2
Trastuzumab